[Renin-angiotensin system and vascular remodelling].
The renin-angiotensin system (RAS) is compartmented between circulating blood and tissue pericellular space. Whereas renin and its substrate diffuse easily from one compartment to another, the angiotensin peptides act in the compartment where there are generated: blood or pericellular space. Renin is trapped in tissues by low and high affinity receptors. In the target cells, angiotensin II/AT1 receptor interaction generates different signals including an immediate functional calcium-dependent response, secondary hypertrophy and a late proinflammatory and procoagulant response. These late pathological effects are mediated by NADPH oxydase-generated free oxygen radicals and NFkappaB activation. In vivo, the tissue binding of renin and the induction of converting enzyme are the main determinants of the involvement of the RAS in vascular remodeling. The target cells of interstitial angiotensin II are mainly the vascular smooth muscle cells and fibroblasts, whereas the endothelial cells and circulating leukocytes are the main targets of circulating angiotensin II. In vivo, angiotensin II participates in the vascular wall hypertrophy associated with hypertension. In diabetes, as in other localized fibrotic cardiovascular diseases, the tissue effects of angiotensin II are mainly dependent on its ability to induce TGF-beta expression. In experimental atherosclerosis, angiotensin II infusion induces aneurysm formation mediated by activation of circulating leucocytes. In these models, the administration of angiotensin II antagonists has beneficial effects on pathological remodeling. Such beneficial effects of angiotensin II antagonists in localized pathological remodeling have not yet been demonstrated in humans.
Michel
Jean-Baptiste
JB
Inserm U.460, CHU Xavier-Bichat, 16, rue Henri Huchard, 75018 Paris, France. jbmichel@bichat.inserm.fr
D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000502:physiology; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D030801:Animals, Genetically Modified; D001161:Arteriosclerosis / Q000503:physiopathology; D001794:Blood Pressure / Q000502:physiology; D001808:Blood Vessels / Q000473:pathology*; D005355:Fibrosis; D006801:Humans; D006978:Hypertension, Renovascular / Q000503:physiopathology; D006984:Hypertrophy; D007249:Inflammation / Q000503:physiopathology; D008954:Models, Biological; D019255:NADPH Oxidases / Q000502:physiology; D017382:Reactive Oxygen Species; D011945:Receptors, Angiotensin / Q000502:physiology; D012084:Renin-Angiotensin System / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000502:physiology
D057911:Angiotensin Receptor Antagonists; D017382:Reactive Oxygen Species; D011945:Receptors, Angiotensin; D016212:Transforming Growth Factor beta; D000804:Angiotensin II; D019255:NADPH Oxidases